Journal of Medicinal Chemistry
Article
(6) Lampert, K.; Machein, U.; Machein, M. R.; Conca, W.; Peter, H.
H.; Volk, B. Expression of matrix metalloproteinases and their tissue
inhibitors in human brain tumors. Am. J. Pathol. 1998, 153, 429−437.
(7) Sternlicht, M. D.; Bergers, G. Matrix metalloproteinases as
emerging targets in anticancer therapy: status and prospects. Emerging
Ther. Targets 2000, 4, 609−633.
(27) auf dem Keller, U.; Bellac, C. L.; Li, Y.; Lou, Y.; Lange, P. F.;
Ting, R.; Harwig, C.; Kappelhoff, R.; Dedhar, S.; Adam, M. J.; Ruth, T.
́
J.; Benard, F.; Perrin, D. M.; Overall, C. M. Novel matrix
metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a
probe for in vivo positron emission tomography imaging in cancer.
Cancer Res. 2010, 70, 7562−7569.
(28) Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The design, structure
and clinical update of small molecular weight matrix metalloproteinase
inhibitors. Curr. Med. Chem. 2004, 11, 2911−2977.
(8) Deryugina, E. I.; Quigley, J. P. Matrix metalloproteinases and
tumor metastasis. Cancer Metastasis Rev. 2006, 25, 9−34.
́
(9) Lopez-Otín, C.; Palavalli, L. H.; Samuels, Y. Protective roles of
matrix metalloproteinases: From mouse models to human cancer. Cell
Cycle 2009, 8 (22), 1−6.
(10) Martin, M. D.; Matrisian, L. M. The other side of MMPs:
Protective roles in tumor progression. Cancer Metastasis Rev. 2007, 26,
717−724.
(11) Overall, C. M.; Kleifeld, O. Tumor microenvironment e
opinion: validating matrix metalloproteinases as drug targets and anti-
targets for cancer therapy. Nat. Rev. Cancer 2006, 6, 227−239.
(12) Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design
and therapeutic application of matrix metalloproteinase inhibitors.
Chem. Rev. 1999, 99, 2735−2776.
(13) Hidalgo, M.; Eckhardt, S. G. Development of matrix
metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst.
2001, 93 (3), 178−193.
(14) Scherer, R. L.; McIntyre, J. O.; Matrisian, L. M. Imaging matrix
metalloproteinases in cancer. Cancer Metastasis Rev. 2008, 27, 679−
690.
(29) Breyholz, H.-J.; Wagner, S.; Faust, A.; Riemann, B.; Holtke, C.;
̈
Hermann, S.; Schober, O.; Schafers, M.; Kopka, K. Radiofluorinated
̈
pyrimidine-2,4,6-triones as molecular probes for noninvasive MMP-
targeted imaging. ChemMedChem 2010, 5, 777−789.
(30) Nuti, E.; Panelli, L.; Casalini, F.; Avramova, S. I.; Orlandini, E.;
Santamaria, S.; Nencetti, S.; Tuccinardi, T.; Martinelli, A.; Cercignani,
G.; D’Amelio, N.; Maiocchi, A.; Uggeri, F.; Rossello, A. Design,
synthesis, biological evaluation, and NMR studies of a new series of
arylsulfones as selective and potent matrix metalloproteinase-12
inhibitors. J. Med. Chem. 2009, 52, 6347−6361.
(31) Tuccinardi, T.; Martinelli, A.; Nuti, E.; Carelli, P.; Balzano, F.;
Uccello-Barretta, G.; Murphy, G.; Rossello, A. Amber force field
implementation, molecular modelling study, synthesis and MMP-1/
MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropox-
ybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Bioorg. Med. Chem.
2006, 14, 4260−4276.
(32) (a) Tamura, Y.; Watanabe, F.; Nakatani, T.; Yasui, K.; Fuji, M.;
Komurasaki, T.; Tsuzuki, H.; Maekawa, R.; Yoshioka, T.; Kawada, K.;
Sugita, K.; Ohtani, M. Highly selective and orally active inhibitors of
type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid
derivatives. J. Med. Chem. 1998, 41, 640−649. (b) Kiyama, R.; Tamura,
Y.; Watanabe, F.; Tsuzuki, H.; Ohtani, M.; Yodo, M. Homology
modeling of gelatinase catalytic domains and docking simulations of
novel sulfonamide inhibitors. J. Med. Chem. 1999, 42, 1723−1738.
(33) Becker, D. P.; Barta, T. E.; Bedell, L. J.; Boehm, T. L.; Bond, B.
R.; Carroll, J.; Carron, C. P.; DeCrescenzo, G. A.; Easton, A. M.;
Freskos, J. N.; Funckes-Shippy, C. L.; Heron, M.; Hockerman, S.;
Howard, C. P.; Kiefer, J. R.; Li, M. H.; Mathis, K. J.; McDonald, J. J.;
Mehta, P. P.; Munie, G. E.; Sunyer, T.; Swearingen, C. A.; Villamil, C.
I.; Welsch, D.; Williams, J. M.; Yu, Y.; Yao, J. Orally active MMP-1
sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metal-
loproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and
cardiovascular disease. J. Med. Chem. 2010, 53, 6653−6680.
(34) Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. Design
and therapeutic application of matrix metalloproteinase inhibitors.
Chem. Rev. 1999, 99 (9), 2735−76.
(15) Yang, Y.; Hong, H.; Zhang, Y.; Cai, W. Molecular imaging of
proteases in cancer. Cancer Growth Metastasis 2009, 2, 13−27.
(16) Wagner, S.; Breyholz, H. J.; Faust, A.; Holtke, C.; Levkau, B.;
̈
Schober, O.; Schafers, M.; Kopka, K. Molecular imaging of matrix
̈
metalloproteinases in vivo using small molecule inhibitors for SPECT
and PET. Curr. Med. Chem. 2006, 13, 2819−2838.
(17) Pimlott, S. L.; Sutherland, A. Molecular tracers for the PET and
SPECT imaging of disease. Chem. Soc. Rev. 2011, 40, 149−162.
(18) Cherry, S. R.; Sorenson, J. A.; Phelps, M. E. Physics in Nuclear
Medicine, 3rd ed.; Saunders: Philadelphia, PA, 2003.
(19) Kubota, K. From tumor biology to clinical PET: A review of
positron emission tomography (PET) in oncology. Ann. Nucl. Med.
2001, 6 (15), 471−486.
(20) Cai, W.; Rao, J.; Gambhir, S. G.; Chen, X. How molecular
imaging is speeding up antiangiogenic drug development. Mol. Cancer
Ther. 2006, 5 (11), 2624−2633.
(21) Kopka, K.; Breyholz, H. J.; Wagner, S.; Law, M. P.; Riemann, B.;
Schroer, S.; Trub, M.; Guilbert, B.; Levkau, B.; Schober, O.; Schafers,
̈
̈
M. Synthesis and preliminary biological evaluation of new radio-
iodinated MMP inhibitors for imaging MMP activity in vivo. Nucl.
Med. Biol. 2004, 2 (31), 257−267.
(35) Rao, J. S. Molecular mechanisms of glioma invasiveness: the role
of proteases. Nat. Rev. Cancer 2003, 3, 489−501.
(36) Kargiotis, O.; Chetty, C.; Gondi, C. S.; Tsung, A. J.; Dinh, D.
H.; Gujrati, M.; Lakka, S. S.; Kyritsis, A. P.; Rao, J. S. Adenovirus-
mediated transfer of siRNA against MMP-2 mRNA results in impaired
invasion and tumor-induced angiogenesis, induces apoptosis in vitro
and inhibits tumor growth in vivo in glioblastoma. Oncogene 2008, 27,
4830−4840.
(22) Fei, X.; Zheng, Q.-H.; Liu, X.; Wang, J.-Q.; Stone, K. L.; Miller,
K. D.; Sledge, G. W.; Hutchins, G. D. Synthesis of MMP inhibitor
radiotracer [11C]CGS-25966, a new potential PET tumor imaging
agent. J. Label. Compd. Radiopharm. 2003, 46, 343−351.
(23) Wagner, S.; Breyholz, H.-J.; Law, M. P.; Faust, A.; Holtke, C.;
̈
Schroer, S.; Haufe, G.; Levkau, B.; Schober, O.; Schafers, M.; Kopka,
̈
̈
(37) Hagemann, C.; Anacker, J.; Haas, S.; Riesner, D.; Schomig, B.;
̈
K. Novel fluorinated derivatives of the broad-spectrum MMP
inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)-
and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for
the molecular imaging of activated MMPs with PET. J. Med. Chem.
2007, 50, 5752−5764.
Ernestus, R. I.; Vince, G. H. Comparative expression pattern of matrix-
metalloproteinases in human glioblastoma cell-lines and primary
cultures. BMC Res. Notes 2010, 3, 293−302.
(38) Aime, S.; Digilio, G.; Bruno, E.; Mainero, V.; Baroni, S.; Fasano,
M. Modulation of the antioxidant activity of HO• scavengers by
albumin binding: a 19F NMR study. Biochim. Biophys. Res. Commun.
2003, 307, 962−966.
(24) Wagner, S.; Breyholz, H.-J.; Holtke, C.; Faust, A.; Schober, O.;
̈
Schafers, M.; Kopka, K. A new 18F-labelled derivative of the MMP
̈
inhibitor CGS 27023A for PET: Radiosynthesis and initial small-
animal PET studies. Appl. Radiat. Isot. 2009, 67, 606−610.
(25) Van de Wiele, C.; Oltenfreiter, R. Imaging probes targeting
matrix metalloproteinases. Cancer Biother. Radiopharm. 2006, 21 (5),
409−417.
(39) Mao, H.; Hajduk, P. J.; Craig, R.; Bell, R.; Borre, T.; Fesik, S. W.
Rational design of diflunisal analogues with reduced affinity for human
serum albumin. J. Am. Chem. Soc. 2001, 123 (43), 10429−10435.
(40) Ghuman, J.; Zunszain, P. A.; Petitpas, I.; Bhattacharya, A. A.;
Otagiri, M.; Curry, S. Structural basis of the drug-binding specificity of
human serum albumin. J. Mol. Biol. 2005, 353, 38−52.
(26) Furomoto, S.; Takashima, K.; Kubota, K.; Ido, T.; Iwata, R.;
Fukuda, H. Tumor detection using 18F-labeled matrix metal-
loproteinase-2 inhibitor. Nucl. Med. Biol. 2003, 30, 119−125.
(41) Prante, O.; Tietze, R.; Hocke, C.; Lober, S.; Harald, H.; Kuwert,
̈
T.; Gmeiner, P. Synthesis, radiofluorination, and in vitro evaluation of
2688
dx.doi.org/10.1021/jm4001743 | J. Med. Chem. 2013, 56, 2676−2689